Navigation Links
Northfield Laboratories Investor Update

EVANSTON, Ill.--(BUSINESS WIRE)--Apr 26, 2007 - Northfield Laboratories Inc. (Nasdaq: NFLD) announced today that its contract research organization has informed the Company that the report of the summary data from its pivotal Phase III trauma trial with PolyHeme(R), the Company's human-hemoglobin based oxygen-carrying red cell substitute, will not be complete until May.

About Northfield Laboratories

Northfield Laboratories Inc. is a leader in developing an oxygen-carrying red blood cell substitute for the treatment of life-threatening blood loss, when an oxygen-carrying fluid is required and red blood cells are not available. PolyHeme(R) is a solution of chemically modified human hemoglobin that requires no cross matching and is therefore compatible with all blood types. It has a shelf life in excess of 12 months. For further information, visit www.northfieldlabs.com.

Forward Looking Statement

This press release may contain forward-looking statements concerning, among other things, Northfield's future business plans and strategies and clinical and regulatory developments affecting our PolyHeme red blood cell substitute product. These forward-looking statements are identified by the use of such terms as "intends," "expects," "plans," "estimates," "anticipates," "should," "believes" and similar terms. These forward-looking statements involve inherent risks and uncertainties. Our actual results may therefore differ materially from those predicted by the forward-looking statements because of various factors and possible events, including the possibility that the final data from our Phase III clinical trial, once available, may not be sufficient to demonstrate the safety or effectiveness of PolyHeme, our ability to obtain FDA approval to market PolyHeme commercially, our ability to obtain Fast Track designation and priority review, the availability of capital to finance our clinical trials and ongoing business operations, our ability to obtain ade
'"/>




Page: 1 2

Related medicine technology :

1. Northfield Laboratories Reports Results of Pivotal Phase III Trauma Study
2. Columbia Laboratories Reports Positive Results from Multi-dose Pharmacokinetic Study of Vaginally-administered Lidocaine
3. Forest Laboratories, Inc. and Cypress Bioscience, Inc. Announce Positive Results of Phase III Study for Milnacipran as a Treatment for Fibromyalgia Syndrome
4. Columbia Laboratories Reports Preliminary Findings from the Ongoing Data Analysis of the Phase III Clinical Study of PROCHIEVE 8% (progesterone gel) to Prevent Preterm Birth
5. Accelrys to Present to Investors at C.E. Unterberg Emerging Growth Opportunities Conference
6. Review of Nexavar Data Presented at ASCO 2007- Investor Conference Call on June 4, 2007
7. Acorda Therapeutics to Host Analyst and Investor Reception
8. Isis Pharmaceuticals Announces Its Participation at the Upcoming ACC 56th Annual Scientific Session in New Orleans and Its Live Analyst/Investor Webcast Presentation
9. Pro-Pharmaceuticals Updates Progress of Clinical Trials & Davanat 505 (b)(2) Filings
10. Avexas Apricitabine Clinical Trial Update
11. Avalon Updates the AVN944 Phase I Hematologic Malignancies Trial
Post Your Comments:
*Name:
*Comment:
*Email:
TAG: Northfield Laboratories Investor Update
(Date:9/19/2014)... SAN DIEGO , Sept. 19, 2014 /PRNewswire/ ... industry leader in bioactive lipid-targeted therapeutics, announced today ... sell 3,605,042 registered shares of common stock and ... The combined purchase price for one registered share ... purchase one unregistered share of common stock will ...
(Date:9/19/2014)... LONDON , September 19, 2014 ... hat Pharma IQ den äußerst erfolgreichen Serialisierungs-Countdown-Kalender aktualisiert, ... abdeckt. Die interaktive PDF, verfügbar unter pharmaserialisation.com ... an dem sie jeweils in Kraft treten. ... der Serialisierung nicht länger um das "ob", sondern ...
(Date:9/19/2014)... Sept. 19, 2014  CytRx Corporation (Nasdaq: ... in oncology, today announced that David J. Haen ... 2014 NewsMakers in the Biotech Industry Conference on Friday, September ... conference will take place at the Millennium Broadway Hotel ... A live and archived webcast of the presentation ...
Breaking Medicine Technology:Lpath, Inc. Announces $12.5 Million Registered Direct Offering 2Lpath, Inc. Announces $12.5 Million Registered Direct Offering 3Pharma IQ stellt weltweite Serialisierungsfristen in seinen Countdown-Kalender 2014 - 2018 2CytRx to Present at BioCentury's 2014 NewsMakers in the Biotech Industry Conference 2CytRx to Present at BioCentury's 2014 NewsMakers in the Biotech Industry Conference 3
... U.S. Food and Drug Administration is warning the public ... law enforcement personnel as part of a continued international ... The criminals call the victims -- who ... or via "telepharmacies" -- and identify themselves as FDA ...
... EDDA Technology, a leading provider of advanced computer ... successful commercial installation of its IQQA®-Liver Enterprise product ... one of the top performing living donor liver ... use EDDA Technology,s IQQA®-Liver Enterprise in conjunction with ...
Cached Medicine Technology:FDA Warns Public of Continued Extortion Scam By FDA Impersonators 2FDA Warns Public of Continued Extortion Scam By FDA Impersonators 3EDDA Technology Successfully Installs IQQA®-Liver at Mayo Clinic in Arizona 2
(Date:9/19/2014)... Forest Hills, NY (PRWEB) September 20, 2014 ... Periodontist Prabha Krishnan DMD in Queens, NY now reminds area ... “With more than 80% of our population affected by gum ... problem any longer.” , For over 20 years Dr. Krishnan ... her Forest Hills office location. “Most patients that come in ...
(Date:9/19/2014)... (PRWEB) September 19, 2014 Recently, ... and announced that JustHost, IX Web Hosting and ... , “As is known to most people, ... partitioning a physical server computer into many servers, ... of running on someone’s own dedicated computer,” the ...
(Date:9/19/2014)... proteins and large protein complexes are notoriously difficult to ... often very difficult, if not impossible, to crystallize, but ... flexible. The result is that when a structure can ... and reveals a mosaic-like spread of protein domains that ... & Brunger. (2014), Acta Cryst . D70, 2241-2255; ...
(Date:9/19/2014)... September 19, 2014 Top10BestSEOHosting.com today ... announces that HostMonster, Arvixe and Bluehost are the ... buy high quality WordPress hosting (including VPS and ... websites for more detailed information. , HostMonster ( ... high-powered service at a fraction of the cost. ...
(Date:9/19/2014)... Texas (PRWEB) September 19, 2014 Singulair, ... the physiologic actions of leukotriene D4 (LTD4). LTD4 belongs ... from a variety of cells, including mast cells and ... receptors. Several studies have determined that there are higher ... asthmatics compared with non-asthmatic individuals. The production of CysLTs ...
Breaking Medicine News(10 mins):Health News:New York Periodontist Dr. Prabha Krishnan Now Raises Awareness about the Dangers of Untreated Decay, Gingivitis and Gum Disease During Self-Awareness Month 2Health News:New York Periodontist Dr. Prabha Krishnan Now Raises Awareness about the Dangers of Untreated Decay, Gingivitis and Gum Disease During Self-Awareness Month 3Health News:Top10BestSEOHosting.com: JustHost is One of the Best VPS Suppliers in 2014 2Health News:A refined approach to proteins at low resolution 2Health News:A refined approach to proteins at low resolution 3Health News:Top10BestSEOHosting.com: They Are Best Windows Web Hosting Suppliers Of 2014 2Health News:Singulair Asthma Market to 2023 – Etiology, Pathophysiology, Diagnosis & Treatment Overview in New Report Available at LifeScienceIndustryResearch.com 2Health News:Singulair Asthma Market to 2023 – Etiology, Pathophysiology, Diagnosis & Treatment Overview in New Report Available at LifeScienceIndustryResearch.com 3Health News:Singulair Asthma Market to 2023 – Etiology, Pathophysiology, Diagnosis & Treatment Overview in New Report Available at LifeScienceIndustryResearch.com 4
... the University of Florida have initiated a project to ... secrets of regeneration from creatures with remarkable powers of ... ,Fueled by about $6 million in private donations, university ... connect scientists who work with adult human stem cells ...
... seventeen patients have been dead due to the infection of ... have died after contracting Clostridium Difficile, commonly known as C ... also reported that few of the patients were infected with ... strain. Major bowel surgery had to be performed on five ...
... the FDA launched a special Web page. This web page ... isotretinoin, sold by Roche// under the brand name Accutane, on ... acne that is not controlled by other treatment forms. FDA ... and severe mental health problems. ,The FDA warning ...
... the cancer drugs to be given freely to patients. They ... 1// and appealed to Northern Ireland's new assembly to follow ... diagnosed with cancer every year. Heather Monteverde from the charity ... as it causes a huge financial burden on them. ...
... at Birmingham's Magnetic Source Imaging Laboratory are studying the ... to learn more about the intricacies of brain pathology. ... the geography of the brain or detect blood flow, ... throw off as they communicate. "You can look at ...
... was shortened as Calgaria. But this has failed to soothe ... insult those afflicted by mental sickness. ,“I realize ... those of us living with mental illness who have to ... who suffers from depression and sits on the board for ...
Cached Medicine News:Health News:UF Launches Project to Bridge the Regeneration Gap 2Health News:UF Launches Project to Bridge the Regeneration Gap 3Health News:Web Page to Warn Against Online Purchase of Isotretinoin 2Health News:MEG Scanners Are Mega Powerful 2
For temporary cardiac pacing after open heart surgery. The zig-zag portion of the heartwire is embedded into the desired area of the myocardium (epicardially)....
For temporary cardiac pacing after open heart surgery. The zig-zag portion of the heartwire is embedded into the desired area of the myocardium (epicardially)....
For temporary cardiac pacing after open heart surgery. The zig-zag portion of the heartwire is embedded into the desired area of the myocardium (epicardially)....
... (RAM) is the first visual examination device that ... in eyes with glaucoma, cataract, and macular disease. ... test each eye easily in under 60 seconds. ... Columbia University in New York City, the RAM ...
Medicine Products: